Emerging Trends in Gastrointestinal Tract Disease Therapies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 381

Special Issue Editors


E-Mail Website
Guest Editor
Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan
Interests: inflammatory bowel disease; fecal microbiota transplantation; cytomegalovirus gastrointestinal diseases

E-Mail Website
Guest Editor
Division of Gastroenterology and Hepatology, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan
Interests: inflammatory bowel disease; therapeutic endoscopy; deep enteroscopy
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
Interests: therapeutic endoscopy; deep enteroscopy; inflammatory bowel disease

Special Issue Information

Dear Colleagues,

In an era marked by unparalleled advancements in gastrointestinal (GI) tract disease therapies, this Special Issue is poised to capture and illuminate the significant progress characterizing this vibrant field. Our mission is to highlight the most recent trends, cutting-edge treatments, and transformative research shaping the future of GI disease management. We cordially invite submissions of original research and in-depth reviews. Our focus encompasses:

  • Innovative therapeutic approaches—exploration of the latest pharmacological advancements, including biologics, small molecules, gene therapies, and their transformative impact on inflammatory bowel disease and other autoimmune-related GI disorders;
  • Endoscopic breakthroughs—advancements in minimally invasive techniques, encompassing endoscopic bariatric therapy, endoscopic anti-reflux therapy, natural orifice transluminal endoscopic surgery, and more, and their efficacy in GI treatment;
  • Gut microbiome research—insightful perspectives on the therapeutic roles of gut microbiota in GI diseases, unveiling novel interventions;
  • Technological integration—integration of AI, machine learning, and telemedicine, revolutionizing the approach and assistance in GI condition treatments.

This Special Issue is committed to providing an expansive platform for knowledge dissemination, fostering synergistic research collaborations, and exemplifying the swift and significant advances in the realm of GI tract disease therapies.

Dr. Puo-Hsien Le
Dr. Jenwei Chou
Dr. Chen-Shuan Chung
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gut microbiota
  • fecal microbiota transplantation
  • inflammatory bowel disease
  • advanced endoscopy
  • endoscopic bariatric therapy
  • endoscopic anti-reflux therapy natural orifice transluminal endoscopic surgery
  • artificial intelligence

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 896 KiB  
Article
Remission Factors for Ustekinumab Treatment of Ulcerative Colitis: A Multicenter Retrospective Study of Real-World Data in Japan
by Masashi Omori, Tomoyoshi Shibuya, Hirotaka Ishino, Yuka Fukuo, Rina Odakura, Masao Koma, Takafumi Maruyama, Kentaro Ito, Mayuko Haraikawa, Kei Nomura, Shintaro Yano, Osamu Nomura, Dai Ishikawa, Mariko Hojo, Taro Osada and Akihito Nagahara
Biomedicines 2024, 12(5), 1119; https://doi.org/10.3390/biomedicines12051119 - 17 May 2024
Viewed by 194
Abstract
Ustekinumab (UST) is an anti–IL-12/23p40 monoclonal antibody used to treat inflammatory bowel disease. The aim of this retrospective, multicenter study was to investigate the effectiveness of UST administration in achieving remission in patients with ulcerative colitis (UC) and to determine patient characteristics that [...] Read more.
Ustekinumab (UST) is an anti–IL-12/23p40 monoclonal antibody used to treat inflammatory bowel disease. The aim of this retrospective, multicenter study was to investigate the effectiveness of UST administration in achieving remission in patients with ulcerative colitis (UC) and to determine patient characteristics that influence its effectiveness. Of 88 UC patients who received UST from March 2020 to August 2023, 47 with traceable data and for whom 56 weeks had elapsed since the start of treatment received UST to induce remission. The remission rates at 8 weeks were 66% overall, 73.7% for Bio Naïve (never used biologics/JAK inhibitors), and 60.7% for Bio Failure (used biologics/JAK inhibitors) groups. Remission rates at 56 weeks were 70.2% overall, 73.7% for Bio Naïve, and 67.9% for Bio Failure groups. Ustekinumab showed good mid-to-long-term results in the induction of remission of UC in both Bio Naïve and Bio Failure groups. The group showing remission at 8 weeks had a significantly higher non-relapse or continuation rate (proportion of patients with no worsened symptoms necessitating surgery/drug change) at 56 weeks. Predictive factors for achieving remission after UST in UC were female gender, low body mass index, and low lymphocyte-to-monocyte ratio. Thus, UST is effective for moderate-to-severe UC. Full article
(This article belongs to the Special Issue Emerging Trends in Gastrointestinal Tract Disease Therapies)
Back to TopTop